Cytomegalovirus-specific cytotoxic t lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 5, 2013, Pages 725-734

  Clancy, Leighton E ^a,b   Blyth, Emily ^a,b,c   Simms, Renee M ^a,b   Micklethwaite, Kenneth P ^a,b   Ma, Chun Kei K ^a   Burgess, Jane S ^a   Antonenas, Vicki ^b   Shaw, Peter J ^d,e   Gottlieb, David J ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c University of Sydney   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adoptive transfer; Immunotherapy; Infection

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; ARTICLE; CELL EXPANSION; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS SPECIFIC CYTOTOXIC T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EX VIVO STUDY; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; PHENOTYPE;

ADULT; AGED; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84876315255     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.01.021     Document Type: Article

References (48)

1. Onorato I.M., Morens D.M., Martone W.J., et al. Epidemiology of cytomegaloviral infections: recommendations for prevention and control. Rev Infect Dis 1985, 7:479-497.
2. Wills M.R., Okecha G., Weekes M.P., et al. Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8(+) T cell response. J Immunol 2002, 168:5455-5464.
3. Beninga J., Kalbacher H., Mach M. Analysis of T helper cell response to glycoprotein H (gpUL75) of human cytomegalovirus: evidence for strain-specific T cell determinants. J Infect Dis 1996, 173:1051-1061.
4. Beninga J., Kropff B., Mach M. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J Gen Virol 1995, 76(Pt 1):153-160.
5. Gandhi M.K., Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004, 4:725-738.
6. + T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202:673-685.
7. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
8. Ozdemir E., Saliba R.M., Champlin R.E., et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007, 40:125-136.
9. Nguyen Q., Champlin R., Giralt S., et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999, 28:618-623.
10. Einsele H., Ehninger G., Hebart H., et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995, 86:2815-2820.
11. Goodrich J.M., Bowden R.A., Fisher L., et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993, 118:173-178.
12. Nichols W.G., Corey L., Gooley T., et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002, 185:273-282.
13. Springer K.L., Chou S., Li S., et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005, 43:208-213.
14. Eckle T., Lang P., Prix L., et al. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant 2002, 30:433-439.
15. Reusser P., Riddell S.R., Meyers J.D., et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78:1373-1380.
16. Quinnan G.V., Kirmani N., Rook A.H., et al. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow transplant recipients. N Engl J Med 1982, 307:7-13.
17. Einsele H., Roosnek E., Rufer N., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-3922.
18. + T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011, 51:591-599.
19. Riddell S.R., Watanabe K.S., Goodrich J.M., et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257:238-241.
20. Walter E.A., Greenberg P.D., Gilbert M.J., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044.
21. Peggs K.S., Verfuerth S., Pizzey A., et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003, 362:1375-1377.
22. Perruccio K., Tosti A., Burchielli E., et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005, 106:4397-4406.
23. Cobbold M., Khan N., Pourgheysari B., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005, 202:379-386.
24. Mackinnon S., Thomson K., Verfuerth S., et al. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 2008, 40:63-67.
25. Peggs K.S., Thomson K., Samuel E., et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011, 52:49-57.
26. Micklethwaite K.P., Clancy L., Sandher U., et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008, 112:3974-3981.
27. Micklethwaite K., Hansen A., Foster A., et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:707-714.
28. Blaise D., Kuentz M., Fortanier C., et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000, 18:537-546.
29. Russell J.A., Brown C., Bowen T., et al. Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996, 17:703-708.
30. Mahmoud H., Fahmy O., Kamel A., et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999, 24:355-358.
31. Bensinger W.I., Clift R., Martin P., et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996, 88:2794-2800.
32. Schmitz N., Dreger P., Suttorp M., et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995, 85:1666-1672.
33. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
34. Schmitz N., Beksac M., Hasenclever D., et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002, 100:761-767.
35. Mielcarek M., Storer B., Martin P.J., et al. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood 2012, 119:2675-2678.
36. Arpinati M., Green C.L., Heimfeld S., et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000, 95:2484-2490.
37. Fraser A.R., Cook G., Franklin I.M., et al. Immature monocytes from G-CSF-mobilized peripheral blood stem cell collections carry surface-bound IL-10 and have the potential to modulate alloreactivity. J Leukoc Biol 2006, 80:862-869.
38. Rutella S., Pierelli L., Bonanno G., et al. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 2002, 100:2562-2571.
39. Chen S.H., Li X., Huang X.J. Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol 2004, 79:178-184.
40. Sloand E.M., Kim S., Maciejewski J.P., et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000, 95:2269-2274.
41. Tayebi H., Kuttler F., Saas P., et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol 2001, 29:458-470.
42. + progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant 2007, 40:851-857.
43. + cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transplant 2005, 36:199-204.
44. Ueda Y., Itoh T., Fuji N., et al. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy. Cancer Immunol Immunother 2007, 56:381-389.
45. + cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells. Clin Cancer Res 1998, 4:2709-2716.
46. Lemarie C., Sugaye R., Kaur I., et al. Purification of monocytes from cryopreserved mobilized apheresis products by elutriation with the Elutra device. J Immunol Methods 2007, 318:30-36.
47. Amir A.L., D'Orsogna L.J., Roelen D.L., et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010, 115:3146-3157.
48. Melenhorst J.J., Leen A.M., Bollard C.M., et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010, 116:4700-4702.